|
Ardelyx, Inc. (ARDX) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Ardelyx, Inc. (ARDX) Bundle
Si es un inversor o analista, esta calculadora DCF (ARDX) es la herramienta perfecta para una valoración precisa. Con datos reales de Ardelyx, Inc., puede ajustar fácilmente los pronósticos y observar los efectos en tiempo real.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.3 | 7.6 | 10.1 | 52.2 | 124.5 | 210.6 | 356.2 | 602.7 | 1,019.6 | 1,725.0 |
| Revenue Growth, % | 0 | 43.36 | 33.36 | 416.57 | 138.61 | 69.18 | 69.18 | 69.18 | 69.18 | 69.18 |
| EBITDA | -84.6 | -85.2 | -150.9 | -61.0 | -55.4 | -187.2 | -316.7 | -535.7 | -906.4 | -1,533.4 |
| EBITDA, % | -1601.42 | -1125.89 | -1494.03 | -116.92 | -44.48 | -88.9 | -88.9 | -88.9 | -88.9 | -88.9 |
| Depreciation | 4.3 | 4.0 | 4.5 | 4.6 | 1.3 | 79.7 | 134.9 | 228.2 | 386.1 | 653.1 |
| Depreciation, % | 82.18 | 52.45 | 44.83 | 8.82 | 1.04 | 37.86 | 37.86 | 37.86 | 37.86 | 37.86 |
| EBIT | -88.9 | -89.2 | -155.4 | -65.6 | -56.6 | -187.6 | -317.4 | -537.0 | -908.5 | -1,537.0 |
| EBIT, % | -1683.6 | -1178.34 | -1538.85 | -125.74 | -45.51 | -89.1 | -89.1 | -89.1 | -89.1 | -89.1 |
| Total Cash | 247.5 | 186.5 | 116.7 | 123.9 | 184.3 | 210.6 | 356.2 | 602.7 | 1,019.6 | 1,725.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .8 | .0 | .5 | 7.7 | 22.0 | 21.8 | 36.8 | 62.3 | 105.4 | 178.4 |
| Account Receivables, % | 14.2 | 0 | 4.97 | 14.83 | 17.7 | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 |
| Inventories | .0 | .0 | .0 | 3.3 | 12.4 | 6.9 | 11.6 | 19.6 | 33.2 | 56.2 |
| Inventories, % | 0.000018935808 | 0 | 0 | 6.29 | 10 | 3.26 | 3.26 | 3.26 | 3.26 | 3.26 |
| Accounts Payable | 2.2 | 5.6 | 4.3 | 10.9 | 11.1 | 79.1 | 133.8 | 226.4 | 383.1 | 648.1 |
| Accounts Payable, % | 41.41 | 74.31 | 42.36 | 20.82 | 8.95 | 37.57 | 37.57 | 37.57 | 37.57 | 37.57 |
| Capital Expenditure | -.3 | -.3 | -1.9 | -.1 | -.3 | -12.3 | -20.9 | -35.3 | -59.8 | -101.1 |
| Capital Expenditure, % | -6.15 | -4.28 | -18.49 | -0.10545 | -0.2764 | -5.86 | -5.86 | -5.86 | -5.86 | -5.86 |
| Tax Rate, % | -0.83486 | -0.83486 | -0.83486 | -0.83486 | -0.83486 | -0.83486 | -0.83486 | -0.83486 | -0.83486 | -0.83486 |
| EBITAT | -89.2 | -89.2 | -155.4 | -65.6 | -57.1 | -187.6 | -317.4 | -537.0 | -908.5 | -1,537.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -83.7 | -81.4 | -154.6 | -65.0 | -79.4 | -46.4 | -168.5 | -285.1 | -482.3 | -815.9 |
| WACC, % | 9.1 | 9.1 | 9.1 | 9.1 | 9.1 | 9.1 | 9.1 | 9.1 | 9.1 | 9.1 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,272.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -832 | |||||||||
| Terminal Value | -11,729 | |||||||||
| Present Terminal Value | -7,590 | |||||||||
| Enterprise Value | -8,862 | |||||||||
| Net Debt | 35 | |||||||||
| Equity Value | -8,897 | |||||||||
| Diluted Shares Outstanding, MM | 219 | |||||||||
| Equity Value Per Share | -40.56 |
What You Will Receive
- Comprehensive Financial Model: Ardelyx, Inc.'s actual data facilitates accurate DCF valuation.
- Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates provide immediate feedback as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Flexible and Reusable: Designed for adaptability, allowing for repeated use in detailed financial forecasts.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Ardelyx, Inc. (ARDX).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to Ardelyx, Inc. (ARDX).
- Customizable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates for Ardelyx, Inc. (ARDX).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Ardelyx, Inc. (ARDX).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis of Ardelyx, Inc. (ARDX).
How It Works
- Download: Obtain the pre-formatted Excel file containing Ardelyx, Inc.'s (ARDX) financial data.
- Customize: Modify projections such as revenue growth, EBITDA margin, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and compare results immediately.
- Make Decisions: Leverage the valuation findings to inform your investment choices.
Why Choose This Calculator for Ardelyx, Inc. (ARDX)?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for Ardelyx, Inc. (ARDX).
- Customizable Inputs: Modify the highlighted cells to explore different financial scenarios for Ardelyx, Inc. (ARDX).
- Detailed Insights: Automatically computes the intrinsic value and Net Present Value for Ardelyx, Inc. (ARDX).
- Preloaded Data: Comes with historical and forecasted data specific to Ardelyx, Inc. (ARDX) for precise analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on Ardelyx, Inc. (ARDX).
Who Should Use This Product?
- Healthcare Professionals: Understand the impact of Ardelyx, Inc. (ARDX) innovations on patient care.
- Researchers: Utilize data from Ardelyx, Inc. (ARDX) to support clinical studies and trials.
- Investors: Evaluate investment opportunities by analyzing the financial metrics of Ardelyx, Inc. (ARDX).
- Pharmaceutical Analysts: Enhance your analysis with detailed reports on Ardelyx, Inc. (ARDX) product pipelines.
- Entrepreneurs: Learn from Ardelyx, Inc. (ARDX) strategies to navigate the biotech industry.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations specifically for Ardelyx, Inc. (ARDX).
- Real-World Data: Ardelyx’s historical and projected financials preloaded for analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to test various scenarios.
- Financial Statements: Full annual and quarterly breakdowns for deeper insights into Ardelyx’s performance.
- Key Ratios: Built-in analysis for profitability, efficiency, and leverage tailored for Ardelyx, Inc. (ARDX).
- Dashboard with Visual Outputs: Charts and tables for clear, actionable results related to Ardelyx, Inc. (ARDX).